Track topics on Twitter Track topics that are important to you
Incyte’s success with Jakafi® (ruxolitinihb) helped persuade MorphoSys that its tafasitamab (MOR208) could also be successfully commercialized by the Wilmington, DE, biopharma, which is licensing the B cell malignancy treatment candidate through a collaboration that could generate more than $2 billion for the German cancer drug developer.
The post Jakafi Success Helps Incyte Land Blockbuster MorphoSys Partnership appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Jakafi Success Helps Incyte Land Blockbuster MorphoSys PartnershipNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...